Posted by Michael Wonder on 01 Apr 2025
GRIN Therapeutics receives PRIME designation from EMA for radiprodil in the treatment of GRIN related neurodevelopmental disorder
1 April 2025 - GRIN Therapeutics today announced that the EMA has granted Priority Medicine (PRIME) designation to radiprodil, the company's investigational, potent negative allosteric modulator selectively targeting the N-methyl-D-aspartate receptor subtype 2B, for the treatment of GRIN-related neurodevelopmental disorder.
The company remains on track to initiate a global pivotal Phase 3 clinical trial for radiprodil for the treatment of GRIN-related neurodevelopment disorder in mid-2025.
